Specifically, NICE suggests considering a DPP-4 inhibitor as a second agent when: The patient has a high risk of hypoglycaemia (making sulfonylureas less suitable) Weight management is a concern and a sulfonylurea's weight-gaining effects are undesirable An SGLT-2 inhibitor is contraindicated or not tolerated NICE NG28 recommends that in patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, an SGLT-2 inhibitor should generally be prioritised often alongside or instead of metformin due to its organ-protective benefits
It signals the pituitary gland to release HGH in a controlled way
The rise of a new class of powerful, FDA-approved medications-specifically Wegovy Michigan and Zepbound Michigan -has completely reshaped the landscape of Detroit weight loss
Management strategies for nausea include slower titration, eating smaller frequent meals, avoiding trigger foods, staying hydrated, and ginger supplementation
4.2 Future directions Future research should focus on confirming these findings in randomized controlled trials (RCTs) to establish causality and evaluate the effectiveness of GLP-1 RAs as therapeutic agents for SUDs
